Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 142
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Clin Endocrinol (Oxf) ; 78(2): 204-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22757971

RESUMEN

BACKGROUND: It is not known if endothelial dysfunction, an important early event in the pathogenesis of atherosclerosis, is present in mild primary hyperparathyroidism (PHPT) and if so, whether it improves following parathyroidectomy. DESIGN: We measured flow-mediated vasodilation (FMD), which estimates endothelial function by ultrasound imaging, in patients prior to and 6 and 12 months after parathyroidectomy. RESULTS: Forty-five patients with mild PHPT [80% female, 61 ± 1 (mean ± SE) years, serum calcium 2·65 ± 0·03 mm (10·6 ± 0·1 mg/dl), PTH 10·5 ± 0·7 pm (99 ± 7 pg/ml), 25-hydroxyvitamin D (25OHD) 70·3 ± 3·7 nm (28·2 ± 1·5 ng/ml)] were studied. Baseline FMD was normal (4·63 ± 0·51%; reference mean: 4·4 ± 0·1%) and was not associated with serum calcium, PTH or 25OHD levels. In the group as a whole, FMD did not change after surgery (6 months: 4·38 ± 0·83%, P = 0·72; 12 months: 5·07 ± 0·74%, P = 0·49). However, in those with abnormal baseline FMD (<2·2%; n = 15), FMD increased by 350%, normalizing by 6 months after surgery (baseline: 0·81± 0·19%; 6 months: 3·18 ± 0·79%, P = 0·02 vs baseline; 12months: 3·68 ± 1·22%, P = 0·04 vs baseline). Baseline calcium, PTH and 25OHD levels did not differ between those with abnormal vs normal FMD, nor did these indices predict postoperative change in FMD. CONCLUSIONS: FMD is generally normal in patients with mild PHPT and is unchanged 1 year after parathyroidectomy. Although FMD may normalize after surgery in patients with baseline abnormalities, data do not support using endothelial dysfunction as an indicator for parathyroidectomy.


Asunto(s)
Endotelio Vascular/fisiopatología , Hiperparatiroidismo Primario/fisiopatología , Adulto , Aterosclerosis/etiología , Enfermedades Cardiovasculares/etiología , Endotelio Vascular/efectos de los fármacos , Femenino , Humanos , Hiperparatiroidismo Primario/complicaciones , Hiperparatiroidismo Primario/cirugía , Masculino , Paratiroidectomía , Factores de Riesgo , Vasodilatación
2.
J Med Ethics ; 34(10): 747-50, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18827108

RESUMEN

AIMS AND BACKGROUND: The present work assessed the impact of two decrees on ethics committees in Italy, aimed at bringing the national laws on the conduct of clinical trials into line with the rest of the EC, and regulating and facilitating not-for-profit research. MATERIAL AND METHODS: Prospectively collected data from an Italian multicentre study were examined with respect to the ethics review process. Administrative and time elements of the review process were audited. Main outcome measures were time between the application submission and the ethics committee definitive opinion, type and number of application submission forms, number of ethics committees that refused fee exemption, and time between the ethics committee approval and the administrative authorisation. RESULTS: A total of 134 local research ethics committees (LRECs) were approached. Application submission procedures and application forms varied greatly; paper submission was mandatory. The median time from submission to approval was 72 days. Only two LRECs refused the fee exemption. The median time from LREC approval to administrative agreement was 50 days and only 9.6% of local authorities came to a verbal agreement with the sponsor. CONCLUSIONS: Italian LRECs are still not sufficiently efficient in complying with the Directive 2001/20/EC requirement (60 days). Better coordination of LRECs work is needed although the optimal level of coordination between them is still not known. In the meantime, national guidelines are needed concerning the application of Directive 2001/20/EC. The behaviour of Italian LRECs towards not-for-profit research was excellent although only the fee exemption was requested.


Asunto(s)
Investigación Biomédica/legislación & jurisprudencia , Comités de Ética/legislación & jurisprudencia , Investigación Biomédica/ética , Investigación Biomédica/normas , Comités de Ética/ética , Comités de Ética/normas , Regulación Gubernamental , Guías como Asunto/normas , Italia
3.
Clin Exp Hypertens ; 30(8): 732-43, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19021024

RESUMEN

The cholinergic marker vesicular acetylcholine transporter (VAChT) was investigated in different cerebral areas of spontaneously hypertensive rats (SHR) by immunochemistry (Western blot analysis) and by immunohistochemistry. SHR were used as an animal model of hypertensive brain damage. The sensitivity of manipulation of cholinergic system on VAChT was assessed in rats treated for four weeks with the acetylcholinesterase (AChE) inhibitor galantamine (3 mg/Kg/day). VAChT concentrations were increased in the brain of control SHR compared to age-matched normotensive Wistar-Kyoto rats. This increase probably represents an up-regulation of VAChT to oppose cholinergic deficits reported in SHR and is countered by galantamine administration. The possibility that cholinergic neurotransmission enhancement may represent a therapeutic strategy in cerebrovascular disease is discussed.


Asunto(s)
Encéfalo/metabolismo , Inhibidores de la Colinesterasa/uso terapéutico , Hipertensión/tratamiento farmacológico , Hipertensión/metabolismo , Proteínas de Transporte Vesicular de Acetilcolina/metabolismo , Animales , Biomarcadores/metabolismo , Presión Sanguínea/efectos de los fármacos , Encéfalo/fisiopatología , Cerebelo/metabolismo , Corteza Cerebral/metabolismo , Fibras Colinérgicas/efectos de los fármacos , Inhibidores de la Colinesterasa/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Galantamina/farmacología , Hipocampo/metabolismo , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY , Transmisión Sináptica/efectos de los fármacos
4.
AJNR Am J Neuroradiol ; 38(5): 862-867, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28341719

RESUMEN

BACKGROUND AND PURPOSE: Dilated perivascular spaces in the brain are associated with greater arterial pulsatility. We hypothesized that perivascular spaces identify individuals at higher risk for systemic and cerebral vascular events. MATERIALS AND METHODS: Stroke-free participants in the population-based Northern Manhattan Study had brain MR imaging performed and were followed for myocardial infarction, any stroke, and death. Imaging analyses distinguished perivascular spaces from lesions presumably ischemic. Perivascular spaces were further subdivided into lesions with diameters of ≤3 mm (small perivascular spaces) and >3 mm (large perivascular spaces). We calculated relative rates of events with Poisson models and hazard ratios with Cox proportional models. RESULTS: The Northern Manhattan Study participants who had MR imaging data available for review (n = 1228; 59% women, 65% Hispanic; mean age, 71 ± 9 years) were followed for an average of 9 ± 2 years. Participants in the highest tertile of the small perivascular space score had a higher relative rate of all deaths (relative rate, 1.38; 95% CI, 1.01-1.91), vascular death (relative rate, 1.87; 95% CI, 1.12-3.14), myocardial infarction (relative rate, 2.08; 95% CI, 1.01-4.31), any stroke (relative rate, 1.79; 95% CI, 1.03-3.11), and any vascular event (relative rate, 1.74; 95% CI, 1.18-2.56). After we adjusted for confounders, there was a higher risk of vascular death (hazard ratio, 1.06; 95% CI, 1.01-1.11), myocardial infarction (hazard ratio, 2.22; 95% CI, 1.12-4.42), and any vascular event (hazard ratio, 1.04; 95% CI, 1.01-1.08) with higher small perivascular space scores. CONCLUSIONS: In this multiethnic, population-based study, participants with a high burden of small perivascular spaces had increased risk of vascular events. By gaining pathophysiologic insight into the mechanism of perivascular space dilation, we may be able to propose novel therapies to better prevent vascular disorders in the population.


Asunto(s)
Encéfalo/patología , Infarto del Miocardio/epidemiología , Accidente Cerebrovascular/epidemiología , Espacio Subaracnoideo/patología , Anciano , Dilatación Patológica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Factores de Riesgo
5.
J Clin Oncol ; 8(4): 672-7, 1990 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2179480

RESUMEN

Between May 1980 and April 1987, 49 children with acute lymphoblastic leukemia (ALL) in isolated testicular and first leukemia relapse (ITR) were enrolled in the Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) multicenter study REC80-ITR. According to the Rome Workshop criteria, 77% were at standard and 23% at high initial prognostic risk. In 33% of the cases, ITR occurred during first treatment. The REC80-ITR protocol consisted of an induction phase regimen of vincristine (VCR), cytarabine (ARA-C), methotrexate (MTX), and asparaginase (L-asp), and bilateral testicular irradiation, and CNS prophylaxis with intrathecal MTX and a maintenance phase with a multidrug rotating regimen. Total treatment duration was 30 months. The median time of observation after ITR was 51 months. The Kaplan-Meier estimates of survival and disease-free survival (DFS) at 4 years were 67.7% and 41%, respectively. Patients who had an ITR on therapy or within the first off-therapy year showed the poorest outcome. The DFS at 3 years was 20%, 47.6%, and 100%, respectively, for children who had an ITR on treatment (n = 16), within the first year of treatment withdrawal (n = 22), or later (n = 10) (P = .001). Patients with an asymptomatic occult testicular infiltrate at treatment discontinuation had a very unfavorable prognosis. Eighty-one percent of second relapses involved the bone marrow. In our experience, children presenting an early ITR (ie, within 6 months of treatment withdrawal) need a very aggressive treatment because of the high probability of an underlying systemic disease. On the other hand, patients with a late ITR seem to have a truly local recurrence and can apparently be cured by standard protocols, as shown in protocol REC80-ITR.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Neoplasias Testiculares/terapia , Trasplante de Médula Ósea , Niño , Preescolar , Terapia Combinada , Humanos , Italia , Masculino , Estudios Multicéntricos como Asunto , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Pronóstico , Recurrencia , Tasa de Supervivencia , Neoplasias Testiculares/patología
6.
J Clin Oncol ; 6(4): 654-8, 1988 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-3357006

RESUMEN

This report deals with a randomized prospective multicentric clinical trial in childhood rhabdomyosarcoma (RMS) conducted to evaluate the toxicity and the effectiveness of dactinomycin (ACT-D) administered as high, single doses v five-day, divided doses administered in combination with vincristine (VCR) and cyclophosphamide (CYC). Fifty-five group III evaluable patients (pts) less than 15 years of age with tumor size greater than 5 cm in diameter, without high-risk features of CNS involvement, and 15 group IV RMS pts were randomized to receive VAC as primary chemotherapy (CT): VCR, 1.5 mg/m2 intravenously (IV) days 1 and 8; CYC, 275 mg/m2 IV days 1 through 5; and ACT-D, 0.45 mg/m2 IV days 1 through 5 every 28 days for three cycles (33 pts), or VAC-M: CYC, 150 mg/m2 intramuscularly (IM) days 1 through 7; VCR, 2.0 mg/m2 IV day 8; and ACT-D, 1.7 mg/m2 IV day 8 every 21 days for four cycles (37 pts). Major responses (complete plus partial responses [PR]) were obtained in 67% of the VAC pts and in 70% of the VAC-M pts. Toxic effects were low, and no increased toxicity was observed in pts treated with high, single-dose ACT-D. These results confirm the effectiveness and feasibility of single, high doses of ACT-D with the advantage of requiring less pt hospitalization.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Dactinomicina/administración & dosificación , Rabdomiosarcoma/tratamiento farmacológico , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Niño , Ciclofosfamida/administración & dosificación , Dactinomicina/toxicidad , Esquema de Medicación , Humanos , Vincristina/administración & dosificación
7.
J Clin Oncol ; 21(3): 530-5, 2003 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-12560445

RESUMEN

PURPOSE: To identify the prognostic factors, treatment, and outcome of children affected by renal cell carcinoma (RCC). PATIENTS AND METHODS: The series included 41 patients (18 males and 23 females) with a median age of 124 months observed at the 11 Italian Association for Pediatric Hematology and Oncology centers from January 1973 to January 2001. Clinical data, surgical notes, pathologic findings, and summaries of therapy were taken from the charts. RESULTS: Seven (17%) of the 41 patients had a papillary histology, and 34 (82.4%) had nonpapillary histology. Eighteen patients (43.9%) had stage I, one patient (2.4%) had stage II, two patients (4.8%) had stage IIIA, 10 patients (24.3%) had stage IIIB, and nine patients (21.9%) had stage IV disease. One patient had a bilateral involvement at diagnosis. Seven patients experienced disease recurrence. Lung and liver were the most common distant lesions and usually were fatal. In this study, the major factor influencing the prognosis was the stage. Event-free survival at 20 years was 53.5% for all patients. Overall survival at 20 years was 54.9% for all patients. CONCLUSION: RCC is a rare disease in children and adolescents. This neoplasm has a different clinical presentation in children compared with adults but the same outcome. In our experience, patients with localized disease could be cured by nephrectomy alone. Prospective studies in a larger number of patients are needed to confirm radiation therapy and biologic response modifiers as effective adjunct therapy in RCC stage III. The alternative therapy seems warranted in patients with advanced disease.


Asunto(s)
Carcinoma de Células Renales/patología , Neoplasias Renales/patología , Recurrencia Local de Neoplasia , Nefrectomía , Adolescente , Carcinoma de Células Renales/radioterapia , Carcinoma de Células Renales/cirugía , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Renales/radioterapia , Neoplasias Renales/cirugía , Masculino , Metástasis de la Neoplasia , Estadificación de Neoplasias , Pronóstico , Factores de Riesgo , Resultado del Tratamiento
8.
J Clin Oncol ; 11(9): 1770-9, 1993 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8355044

RESUMEN

PURPOSE: To define factors that influence outcome in children with localized but unresectable neuroblastoma by retrospective investigation of response to therapy and outcome in 21 Italian institutions. PATIENTS AND METHODS: Of 145 assessable children diagnosed between 1979 and 1990, 77 were treated between 1979 and 1984 with three consecutive standard-dose (SD) protocols, and 68 between 1985 and 1990 with a high-dose (HD) protocol. All protocols included chemotherapy, followed by resection of primary tumor if feasible. If at least partial resection was achieved, consolidation therapy followed, except that from 1985 onward, patients considered disease-free following surgery received no further treatment. RESULTS: Ninety-four of 145 patients (65%) achieved a complete response (CR) or partial response (PR) with chemotherapy and 75 (52%) subsequently underwent complete resection of the primary tumor. Eighty-one patients are alive (73 without disease, eight with disease), 63 have died, and one is lost to follow-up. The 5-year overall survival (OS) rate is 55% and progression-free survival (PFS) rate 50%. Both OS and PFS correlated with response to chemotherapy, removal of primary tumor, HD therapy, and serum lactate dehydrogenase (LDH) levels. Infants (< 1 year), independent of primary tumor site, and children aged 1 to 15 years with a nonabdominal primary tumor, did better compared with children aged 1 to 15 years with an abdominal primary tumor (PFS, 72% and 64% v 30%; P < .001 and < .01, respectively). Outcome of this last group improved with the HD protocol (PFS, 40% v 23%; P = .01). CONCLUSION: In children with unresectable neuroblastoma, risk categories can be defined by age and primary tumor site. HD chemotherapy should be investigated for the poor-risk category age 1 to 15 years with an abdominal primary tumor.


Asunto(s)
Neuroblastoma/terapia , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Análisis Multivariante , Estadificación de Neoplasias , Neuroblastoma/tratamiento farmacológico , Neuroblastoma/patología , Neuroblastoma/cirugía , Inducción de Remisión , Análisis de Supervivencia , Resultado del Tratamiento
9.
J Am Coll Cardiol ; 24(1): 159-64, 1994 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8006260

RESUMEN

OBJECTIVES: The purpose of this study was to investigate left atrial appendage size, function and thrombus prevalence in patients with atrial "fibrillation-flutter." BACKGROUND: Thrombus formation and peripheral embolization in atrial fibrillation are related to left atrial appendage dysfunction. Embolization occurs less frequently in atrial flutter. It is not known whether the atrial appendage in fibrillation-flutter, which has an intermediate appearance on the surface electrocardiogram (ECG), has distinct characteristics that could affect thrombus formation. METHODS: Sixty-one patients with atrial tachyarrhythmias underwent transesophageal echocardiographic examination of the left atrial appendage. Appendage area, peak emptying velocity and the presence of thrombus and spontaneous echo contrast were determined. The results for 14 patients with fibrillation-flutter (based on ECG fibrillatory wave characteristics) were compared with those for 30 patients with atrial fibrillation and 17 patients with atrial flutter. RESULTS: Both fibrillation-flutter and atrial fibrillation were associated with chaotic appendage flow patterns with similarly low peak emptying velocities (18 +/- 8 and 17 +/- 10 cm/s, mean +/- 1 SD, respectively). Atrial flutter was associated with a regular pattern of appendage contraction and a significantly higher peak emptying velocity (42 +/- 18 cm/s, p < 0.0001). Mean appendage area was similar for fibrillation-flutter and fibrillation (6.3 +/- 2.2 and 6.7 +/- 2.1 cm2, respectively) but was significantly smaller for atrial flutter (5.3 +/- 1.4 cm2, p < 0.05). The prevalence of left atrial appendage thrombus was similar for fibrillation-flutter and atrial fibrillation (40% and 29%, respectively), whereas no patient with atrial flutter had a thrombus (p < 0.05). Similarly, the presence of spontaneous echo contrast was higher for fibrillation-flutter (50%) and atrial fibrillation (40%) than for atrial flutter (6%, p < 0.05). CONCLUSIONS: Left atrial appendage size and function in atrial fibrillation-flutter are indistinguishable from those of typical atrial fibrillation, and the frequency of thrombus and spontaneous echo contrast is similarly high. This is in contrast to atrial flutter, which is characterized by a smaller, more contractile left atrial appendage and a lower frequency of thrombus and spontaneous echo contrast.


Asunto(s)
Fibrilación Atrial/diagnóstico por imagen , Aleteo Atrial/diagnóstico por imagen , Función del Atrio Izquierdo , Ecocardiografía Transesofágica , Cardiopatías/diagnóstico por imagen , Trombosis/diagnóstico por imagen , Anciano , Análisis de Varianza , Fibrilación Atrial/complicaciones , Fibrilación Atrial/epidemiología , Fibrilación Atrial/fisiopatología , Aleteo Atrial/complicaciones , Aleteo Atrial/epidemiología , Aleteo Atrial/fisiopatología , Distribución de Chi-Cuadrado , Ecocardiografía Transesofágica/instrumentación , Ecocardiografía Transesofágica/métodos , Ecocardiografía Transesofágica/estadística & datos numéricos , Electrocardiografía , Femenino , Cardiopatías/epidemiología , Cardiopatías/etiología , Cardiopatías/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Trombosis/epidemiología , Trombosis/etiología , Trombosis/fisiopatología
10.
J Am Coll Cardiol ; 24(3): 671-5, 1994 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8077537

RESUMEN

OBJECTIVES: This study attempted to document the incidence of pulmonary vein complications and their potential relation to clinical outcome in patients after lung transplantation. BACKGROUND: Several case reports have documented the presence of pulmonary venous thrombosis causing graft failure in patients after lung transplantation. Because the presentation of these complications mimics that of other postoperative problems, the true incidence of pulmonary vein abnormalities remains unclear. Transesophageal echocardiography is ideally suited to examine the pulmonary veins in the postoperative setting. METHODS: Twenty-one consecutive patients undergoing lung transplantation at our institution underwent transesophageal echocardiography within 32 days of transplantation (mean [+/- SD] 6.5 +/- 7.8 days). Special attention was placed on visualizing the pulmonary veins. RESULTS: Six (29%) of the 21 patients were noted to have abnormalities of the pulmonary veins in the vicinity of the anastomotic site. After follow-up of 30 days, 4 of these patients (67%) had significant cardiovascular morbidity, and 2 died, compared with 1 (7%) of 15 patients with normal pulmonary veins (p = 0.03). The degree of obstruction of the pulmonary vein appeared to correlate with short-term outcome. CONCLUSIONS: Abnormalities of the pulmonary veins are common after lung transplantation and are easily identified by transesophageal echocardiography. Occlusive thrombi appear to be detrimental to short-term outcome.


Asunto(s)
Ecocardiografía Transesofágica , Trasplante de Pulmón/efectos adversos , Venas Pulmonares , Trombosis/diagnóstico por imagen , Adulto , Anciano , Distribución de Chi-Cuadrado , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Trombosis/epidemiología
12.
Arterioscler Thromb Vasc Biol ; 20(9): 2039-44, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10978246

RESUMEN

Asymmetric dimethylarginine (ADMA), a compound detectable in human plasma, is an endogenous inhibitor of NO synthase. Endothelial dysfunction is an early event in atherogenesis, and large-vessel atherosclerosis is a major cause of morbidity and mortality in patients with type 2 diabetes mellitus. Fifty patients with type 2 diabetes mellitus were studied at baseline and 5 hours after ingestion of a high-fat meal. Plasma ADMA measured by using high-performance liquid chromatography increased from 1.04+/-0.99 to 2.51+/-2.27 micromol/L (P:<0.0005). Brachial arterial vasodilation after reactive hyperemia, a NO-dependent function, measured by high-resolution ultrasound, decreased from 6.9+/-3.9% at baseline to 1.3+/-4.5% (P:<0.0001). These changes occurred in association with increased plasma levels of triglycerides and very low density lipoprotein triglycerides, with reduced low density lipoprotein cholesterol and high density lipoprotein cholesterol, and with no changes in total cholesterol. The increase in plasma ADMA in response to a high-fat meal was significantly and inversely related to the decrease in percent vasodilation. In 10 of the subjects studied with a similar protocol on another day, no significant changes in the brachial artery flow responses or in plasma ADMA were observed 5 hours after ingestion of a nonfat isocaloric meal. The data suggest that ADMA may contribute to abnormal blood flow responses and to atherogenesis in type 2 diabetics.


Asunto(s)
Arginina/análogos & derivados , Arginina/sangre , Diabetes Mellitus Tipo 2/sangre , Grasas de la Dieta/farmacología , Endotelio Vascular/efectos de los fármacos , Adulto , Anciano , Endotelio Vascular/fisiología , Femenino , Humanos , Lípidos/sangre , Masculino , Persona de Mediana Edad , Triglicéridos/sangre , Vasodilatación/efectos de los fármacos
13.
Stroke ; 31(11): 2623-7, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11062285

RESUMEN

BACKGROUND AND PURPOSE: Atherosclerotic plaque of the proximal portion of the aorta is associated with an increased risk of ischemic stroke in the elderly. Different cutoffs of plaque thickness have been used in the literature for risk stratification and have been applied to both men and women. However, the assumption that the relationship between plaque thickness and stroke risk is the same in the 2 genders has not been proven. The aim of this study was to evaluate whether the prevalence of different degrees of aortic plaque thickness differed in men and women with ischemic stroke. METHODS: We performed transesophageal echocardiography in 152 patients aged >59 years with acute ischemic stroke (76 men and 76 women) and in 152 control subjects of similar age (70 men and 82 women). Odds ratios (ORs) for ischemic stroke with 95% CIs for different plaque thickness definitions were calculated for the overall group and separately for men and women by logistic regression analysis after adjusting for age, arterial hypertension, and hypercholesterolemia. RESULTS: Aortic plaques >/=4 mm were significantly more frequent in men than in women (31.5% versus 20.3%, respectively; P:=0.025) and were associated with ischemic stroke in both men (adjusted OR 6.0, CI 2.1 to 16.8) and women (adjusted OR 3. 2, CI 1.2 to 8.8). However, plaques 3 to 3.9 mm in thickness had a significant association with stroke in women (adjusted OR 4.8, CI 1. 7 to 15.0) but not in men (adjusted OR 0.8, CI 0.2 to 3.0). Plaques <3 mm were not associated with a significantly increased stroke risk for either sex. CONCLUSIONS: Smaller aortic plaques are significantly associated with ischemic stroke in women but not in men. If the increased prevalence of smaller plaques in women is confirmed to be associated with increased risk for embolic stroke, different cutoff points may have to be adopted in men and women for risk stratification and for decisions regarding medical intervention.


Asunto(s)
Enfermedades de la Aorta/epidemiología , Arteriosclerosis/epidemiología , Accidente Cerebrovascular/epidemiología , Anciano , Ecocardiografía/estadística & datos numéricos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Prevalencia , Factores de Riesgo , Factores Sexuales , Accidente Cerebrovascular/diagnóstico
14.
Curr Med Chem ; 8(13): 1649-60, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11562284

RESUMEN

The prevention of anthracycline cardiotoxicity is particularly important in children who can be expected to survive for decades after cancer chemotherapy with these agents. The rapid increase in clinical toxicity at doses greater than 550 mg/m(2) of doxorubicin (DOX) has made this dose the limiting one in order to avoid DOX-induced cardiac failure. However, arbitrary dose limitation is inadequate because of variability of individual tolerance. Decreasing myocardial concentrations of anthracyclines (ANT) and their metabolites and schedule modification of administration can reduce anthracycline cardiotoxicity. Anthracycline structural analogues such as epirubicin, idarubicin and mitoxantrone have been used in clinical practice. In addition, the liposomal ANT, which can be incorporated into a variety of liposomal preparations, are a new class of agents that may permit more specific organ targeting of ANT, thereby producing less cardiac toxicity. Much interest has focused on the administration of ANT in conjunction with another agent that will selectively attenuate the cardiotoxicity. As is known, the ANT chelate iron and the DOX-iron complex catalyzes the formation of extremely reactive hydroxyl radicals. Many agents, such as dexrazoxane (DEX), able to remove iron from DOX, have been investigated as anthracycline cardioprotectors. Clinical trials of DEX have been conducted in children and significant short-term cardioprotection with no evidence of interference with antitumor activity has been demonstrated. Whether long-term cardiac toxicity will also be avoided in surviving patients has not yet been determined.


Asunto(s)
Antraciclinas/efectos adversos , Cardiotónicos/uso terapéutico , Cardiopatías/inducido químicamente , Cardiopatías/prevención & control , Quelantes del Hierro/uso terapéutico , Antraciclinas/química , Antraciclinas/farmacocinética , Antineoplásicos/efectos adversos , Biotransformación , Niño , Relación Dosis-Respuesta a Droga , Doxorrubicina/efectos adversos , Humanos , Liposomas
15.
Neurology ; 43(8): 1533-5, 1993 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8351007

RESUMEN

BACKGROUND AND PURPOSE: Paradoxical embolism through a patent foramen ovale is a contributory mechanism to stroke and may be diagnosed by contrast echocardiography. The intracranial distribution of these emboli has not been previously reported. METHODS: We used transcranial Doppler combined with agitated saline contrast injection to determine whether there was a preferential distribution of the contrast into the anterior or posterior intracranial circulation of patients with an acute stroke or transient ischemic attack. RESULTS: Forty-nine patients were studied--27 men and 22 women, with a mean age of 62.7 +/- 13.3 years (range, 29 to 85 years). Microcavitations were detected in the proximal right middle cerebral artery in 12 of 49 patients (24%). A patent foramen ovale was confirmed in all cases by simultaneous transesophageal echocardiography. Of the 12 patients, microcavitations were also detected in the proximal basilar artery in nine (75%). CONCLUSIONS: While paradoxical embolism appears to occur more frequently in the anterior circulation, the high rate of detection of microcavitations in the basilar artery suggests that paradoxical embolism to the posterior intracranial circulation may be more frequent than generally believed.


Asunto(s)
Ecocardiografía Doppler , Embolia y Trombosis Intracraneal/diagnóstico por imagen , Adulto , Anciano , Anciano de 80 o más Años , Trastornos Cerebrovasculares/diagnóstico por imagen , Trastornos Cerebrovasculares/etiología , Femenino , Defectos del Tabique Interatrial/diagnóstico por imagen , Humanos , Embolia y Trombosis Intracraneal/complicaciones , Ataque Isquémico Transitorio/diagnóstico por imagen , Ataque Isquémico Transitorio/etiología , Masculino , Persona de Mediana Edad
16.
Neurology ; 46(6): 1560-6, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8649549

RESUMEN

PURPOSE: Proximal aortic atheromas have been suggested as a potential ischemic stroke determinant in the elderly, especially in cases of unexplained (cryptogenic) stroke. Our aim was to assess the potential role of proximal aortic atheromas as an independent risk factor for stroke by comparing their frequency in patients with acute ischemic stroke and in stroke-free control subjects. The frequency of atheromas was also compared among different ethnic groups. PATIENTS AND METHODS: A case-control study was conducted in 106 patients with acute ischemic stroke and 114 stroke-free control subjects. The presence of atheromas of the proximal portion of the aorta was assessed by biplane transesophageal echocardiography. Atheromas were categorized on the basis of their thickness (0.2 to 0.4 cm, small; > or = 0.5 cm, large) and complexity (i.e., ulceration or mobility). The association between aortic atheromas and ischemic stroke was tested, controlling for patients' demographic variables and stroke risk factors. In stroke patients, subgroup analyses were performed to test the associations between aortic atheromas and stroke diagnostic subtypes (determined cause versus cryptogenic) and presence and degree of carotid stenoses by duplex Doppler examination. RESULTS: The frequency of large aortic atheromas was greater in stroke patients than in controls (26% versus 13%; crude odds ratio [OR] 2.4, 95% CI 1.2 to 4.7); ulcerated or mobile atheromas also tended to be more frequent in stroke patients (12% versus 5%; OR 2.5, 95% CI 1.0 to 6.8). Differences were entirely attributable to the subgroup of patients aged 60 years or older, in whom the frequency of ulcerated or mobile atheromas was particularly high among cryptogenic stroke patients (22% versus 8% in control subjects; OR 3.4, 95% CI 1.1 to 11.2). Multivariate analysis showed the presence of large atheromas to be independently associated with stroke in the entire study group (adjusted OR 2.6, 95% CI 1.1 to 5.9) and in the older subgroup (OR 2.4, 95% CI 1.1 to 5.7). Carotid stenosis > or = 60% was more frequent with increasing size and complexity of aortic atheromas but had low predictive value (16%) for presence of large atheromas; moreover, 36% of patients with mild or no carotid stenosis had large or complex aortic atheromas. No significant differences were found in the frequency of atheromas by ethnic group. CONCLUSIONS: Proximal aortic atheromas > or = 0.5 cm in size are a risk factor for ischemic stroke in patients aged 60 years or older. Ulcerated or mobile atheromas may play a role in explaining some cryptogenic strokes in the elderly. The risk for stroke of patients with aortic atheromas may be similar across different ethnic groups. The absence of carotid stenosis does not exclude aortic atheromas as a potential cause for ischemic stroke.


Asunto(s)
Enfermedades de la Aorta/diagnóstico por imagen , Arteriosclerosis/diagnóstico por imagen , Isquemia Encefálica/etiología , Ecocardiografía Transesofágica , Enfermedad Aguda , Negro o Afroamericano , Anciano , Aorta Torácica , Enfermedades de la Aorta/complicaciones , Enfermedades de la Aorta/etnología , Arteriosclerosis/complicaciones , Arteriosclerosis/etnología , Isquemia Encefálica/etnología , Enfermedades Cardiovasculares/epidemiología , Estenosis Carotídea/epidemiología , Comorbilidad , Diabetes Mellitus/epidemiología , Femenino , Hispánicos o Latinos , Humanos , Masculino , Persona de Mediana Edad , Ciudad de Nueva York/epidemiología , Factores de Riesgo , Fumar/epidemiología , Población Blanca
17.
Am J Med ; 84(3A): 133-5, 1988 Mar 11.
Artículo en Inglés | MEDLINE | ID: mdl-3218652

RESUMEN

Diastolic function of the left ventricle was assessed in 29 untreated patients with mild to moderate hypertension and in 21 normotensive control subjects using gated radionuclide ventriculography. In hypertensive patients, the time to peak filling rate was significantly longer (p less than 0.01) than that in control subjects, and first-third filling fraction and peak filling rate were significantly reduced (p less than 0.001). The ejection fraction and peak ejection rate were also significantly reduced in hypertensive patients (p less than 0.001). No relation was observed between diastolic functional impairment and age, cardiac hypertrophy, or severity of hypertension. Thus, early impairment of ventricular filling is present in hypertension, even in young patients without evidence of cardiac hypertrophy.


Asunto(s)
Corazón/diagnóstico por imagen , Hipertensión/diagnóstico por imagen , Adulto , Anciano , Ecocardiografía , Femenino , Corazón/fisiopatología , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Contracción Miocárdica , Cintigrafía , Volumen Sistólico , Sístole
18.
J Hypertens ; 3(3): 255-9, 1985 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-4020132

RESUMEN

Screening for hypertension in the community leads to the identification of hypertensive people not previously detected, and those detected but inadequately treated or not treated at all. The aim of the present study was to assess the long-term efficacy of screening for blood pressure control in a general population. During 1981, 2139 parents of high school students were invited to our institute for a blood pressure measurement; 1533 persons (71.7%) attended the screening; 239 of them (15.6%) were found to be hypertensive (diastolic blood pressure greater than or equal to 95 mmHg or already receiving antihypertensive treatment). Among the hypertensives, 42.3% did not know that they had high blood pressure, and only 7.5% had their blood pressure controlled by treatment. After being informed about the importance of lowering their blood pressure levels, all hypertensives were invited again to the institute for a further evaluation. Two hundred and two persons (84.5%) attended the re-examination. Of these, 154 (76.2%) were still hypertensive. Of the 202, 151 (74.7%) had contacted their physicians. The most common advice was to make further measurements of blood pressure over a period of time, followed by laboratory tests. The proportion of treated hypertensives rose from the initial 33.1% to 53.9%, but in about half the patients normalization of blood pressure was not achieved. Physicians tended to treat only people with moderate to severe hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Hipertensión/epidemiología , Tamizaje Masivo , Adulto , Servicios de Salud Comunitaria , Femenino , Humanos , Italia , Masculino , Persona de Mediana Edad
19.
Neuroscience ; 122(1): 205-11, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14596861

RESUMEN

The expression and microanatomical localization of the muscarinic cholinergic m5 receptor subtype was investigated in rat circle of Willis and pial arteries by in situ hybridization, immunoblotting and immunohistochemistry. In situ hybridization histochemistry revealed a strong signal in the endothelium of circle of Willis and pial arteries and a moderate signal in the tunica media of the same arteries, within smooth muscle. Exposure of membranes of arteries to anti-m5 receptor protein antibodies caused the development of a band of approximately 81 kDa. Immunohistochemistry revealed the accumulation of m5 receptor protein immunoreactivity primarily within endothelium of circle of Willis and cerebral arteries and to a lesser extent in the tunica media, within smooth muscle. Medium (external diameter 200-100 microm) and small-sized (external diameter smaller than 100 microm) pial arteries displayed a significantly higher immune staining than large-sized pial arteries or circle of Willis arteries. The above data that are consistent with recent functional studies reporting cholinergic dilation of cerebral blood vessels mediated via a m5 receptor, have shown that both endothelial and muscular components of cerebral arteries synthesize and express a muscarinic m5 receptor. In view of the peculiar localization in cerebral vessels, handling of the muscarinic m5 receptor may be considered as an approach in the treatment of cerebrovascular disease.


Asunto(s)
Arterias Cerebrales/química , Círculo Arterial Cerebral/química , Piamadre/irrigación sanguínea , Receptor Muscarínico M5/análisis , Animales , Western Blotting , Inmunohistoquímica , Hibridación in Situ , Masculino , Ratas , Ratas Wistar
20.
J Nucl Med ; 35(9): 1429-35, 1994 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8071687

RESUMEN

UNLABELLED: The rationale of this study was the evaluation of response to chemotherapy in children with advanced neuroblastoma using currently available diagnostic modalities. METHODS: Iodine-131-metaiodobenzylguanidine (MIBG) imaging and 24-hr urinary vanillylmandelic acid (VMA) measurement were evaluated in 14 patients (7 males, 7 females, age range: 2-68 mo) with advanced neuroblastoma both pre- and postchemotherapy (5.6 +/- 2.8 mo) as well as serum ferritin (FER) and neuron-specific enolase (NSE) levels in 9 and 8 patients, respectively. MIBG images were qualitatively compared in each patient. RESULTS: Prechemotherapy, a total of 39 abnormal foci of MIBG uptake was detected. Postchemotherapy, 15 of these showed unchanged MIBG uptake, 7 had decreased uptake and 17 showed no uptake. In addition, four new abnormal foci of uptake were found. Postchemotherapy, a significant reduction of abnormal MIBG uptake (p < 0.01) was observed using a lesion-by-lesion analysis. When biochemical and MIBG postchemotherapy changes were compared, a significant relationship was found only between MIBG and VMA results (r = 0.84, p < 0.01). CONCLUSIONS: In postchemotherapy follow-up of children with advanced neuroblastoma, laboratory evaluation using VMA, FER and NSE measurements reflect only the global functional status of the disease, and are not helpful in defining the response of individual tumor lesions to treatment. Conversely, qualitative analysis using MIBG imaging may allow lesion-by-lesion evaluation of the heterogeneity of neuroblastoma response to chemotherapy. In this setting, changes in MIBG uptake are mirrored by the changes in catecholamine production, as measured by VMA levels.


Asunto(s)
Radioisótopos de Yodo , Yodobencenos , Neuroblastoma/diagnóstico por imagen , Neuroblastoma/tratamiento farmacológico , 3-Yodobencilguanidina , Neoplasias de las Glándulas Suprarrenales/diagnóstico por imagen , Neoplasias de las Glándulas Suprarrenales/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Neoplasias del Mediastino/diagnóstico por imagen , Neoplasias del Mediastino/tratamiento farmacológico , Cintigrafía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA